

# Methylprednisolone



Statut de médicament essentiel ✓

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.4. Hormones and antihormones

EMLc

Codes ATC: H02AB04

Indication	Lymphoid leukaemia, not elsewhere classified Code ICD11: 2C03.3
INN	Methylprednisolone
Type de médicament	Chemical agent
Type de liste	Liste complémentaire (EML) (EMLc)
Formulations	Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate) (EMLc) ; 40 mg per mL in 5 mL multi-dose vial (as sodium succinate) (EMLc) ; 80 mg per mL in 1 mL single-dose vial (as sodium succinate) (EMLc)
Historique des statuts LME	Ajouté pour la première fois en 2011 (TRS 965) Modifié en 2015 (TRS 994)
Sexe	Tous
Âge	Enfants (1 mois - 12 ans)
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets. <input checked="" type="checkbox"/>
Balises	Cancer
Wikipédia	<a href="#">Methylprednisolone</a>
DrugBank	<a href="#">Methylprednisolone</a>

## Résumé des preuves et recommandation du comité d'experts

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for methylprednisolone injection on the complementary list of the EMLc for use in treatment protocols for acute lymphoblastic leukaemia was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for acute lymphoblastic leukaemia is attached.

Rapport du comité d'experts

